OMEICOS Therapeutics is a spin-off from the MDC Berlin. Since its founding, OMEICOS has continued a close collaboration with the working groups of OMEICOS’ co-founders
Dr. Wolf-Hagen Schunck and Dr. Dominik Müller to fully elucidate the molecular mode of action of natural Cytochrome P450-dependent metabolites of omega-3 fatty acids and their synthetic analogs activating a novel protective pathway in cardiomyocytes and other cell types.
OMEICOS Therapeutics is working closely together with the research group of Dr. Stanley Nattel to investigate the anti-arrhythmic effect of OMEICOS’ compounds in atrial fibrillation.
Dr. Stanley Nattel’s lab is one of the world’s leading research teams focused on clinically-relevant mechanisms of atrial fibrillation, cardiac remodeling, ion channel molecular physiology and mechanisms of drug action.